Across TCGA pan-cancer cohorts, ZNF783 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF783 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ZNF783 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF783 expression acts as an unfavorable survival marker, although some lineages such as SCLC and LUAD show a favorable association.

THYM, HNSC, and SCLC are the cancer types where ZNF783 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
HNSC	OS	Median	IV	0.098	0.733	<.001	15	view →
SCLC	DFS	Median	II,III,IV	1.000	0.303	.027	6	view →
LUAD	OS	Median	III,IV	0.508	0.321	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF783 tumor-vs-normal RNA expression · all ZNF783 data types